[The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance].
Efficacy was studied of acarbose in patients with type II diabetes mellitus during the development of secondary sulfamide resistance. 63 patients were evaluated. Studies were made involving glycemia on an empty stomach, postprandial glycemia and 24-h glucosuria in order that we might learn about the above drug's efficacy. High confidence level decrease in postprandial glycemia was recorded as was significant reduction in diurnal glucosuria.
Gendeleka
G F
GF
D020909:Acarbose; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004341:Drug Evaluation; D004351:Drug Resistance; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D065089:Glycoside Hydrolase Inhibitors; D006029:Glycosuria / Q000652:urine; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D013424:Sulfanilamides / Q000037:antagonists & inhibitors*; D014312:Trisaccharides / Q000009:adverse effects / Q000627:therapeutic use*
D001786:Blood Glucose; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D013424:Sulfanilamides; D014312:Trisaccharides; D020909:Acarbose
Primenenie ingibitora al'fa-gliukozidazy akarbozy dlia lecheniia sakharnogo diabeta II tipa pri vtorichnoĭ sul'fanilamidorezistentnosti.